Clinical trials: Early Adult Lung Function
Asthma
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).
- Trial name
- MODIFY (NCT07456033)
- Testing
- Depemokimab
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 456 people
- Sponsor
- GlaxoSmithKline